Verve Therapeutics, Inc. (VERV)
Jul 25, 2025 - VERV was delisted (reason: acquired by LLY)
11.13
0.00 (0.00%)
Inactive ยท Last trade price on Jul 24, 2025
Verve Therapeutics Employees
Verve Therapeutics had 274 employees as of December 31, 2024. The number of employees increased by 19 or 7.45% compared to the previous year.
Employees
274
Change (1Y)
19
Growth (1Y)
7.45%
Revenue / Employee
$217,566
Profits / Employee
-$660,606
Market Cap
994.14M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 274 | 19 | 7.45% |
| Dec 31, 2023 | 255 | 51 | 25.00% |
| Dec 31, 2022 | 204 | 91 | 80.53% |
| Dec 31, 2021 | 113 | - | - |
VERV News
- 1 year ago - Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - PRNewsWire
- 1 year ago - Lilly and Verve announce expiration of Verve tender offer - PRNewsWire
- 1 year ago - VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV - Business Wire
- 1 year ago - Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion - WSJ
- 1 year ago - Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say - Reuters
- 1 year ago - Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - PRNewsWire
- 1 year ago - Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. - Barrons
- 1 year ago - Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - Reuters